A326030 Stock Overview
A pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
SK Biopharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩101,900.00 |
| 52 Week High | ₩130,000.00 |
| 52 Week Low | ₩72,600.00 |
| Beta | 0.94 |
| 1 Month Change | 4.09% |
| 3 Month Change | -6.34% |
| 1 Year Change | 8.98% |
| 3 Year Change | 3.87% |
| 5 Year Change | n/a |
| Change since IPO | -19.76% |
Recent News & Updates
SK Biopharmaceuticals Co., Ltd. (KRX:326030) Shares Could Be 47% Below Their Intrinsic Value Estimate
Nov 27
There May Be Underlying Issues With The Quality Of SK Biopharmaceuticals' (KRX:326030) Earnings
Aug 22SK Biopharmaceuticals Co., Ltd. (KRX:326030) Looks Just Right With A 25% Price Jump
Aug 21Recent updates
SK Biopharmaceuticals Co., Ltd. (KRX:326030) Shares Could Be 47% Below Their Intrinsic Value Estimate
Nov 27There May Be Underlying Issues With The Quality Of SK Biopharmaceuticals' (KRX:326030) Earnings
Aug 22SK Biopharmaceuticals Co., Ltd. (KRX:326030) Looks Just Right With A 25% Price Jump
Aug 21Does This Valuation Of SK Biopharmaceuticals Co., Ltd. (KRX:326030) Imply Investors Are Overpaying?
May 22SK Biopharmaceuticals Co., Ltd. (KRX:326030) Not Lagging Industry On Growth Or Pricing
Apr 09Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?
Feb 27Shareholder Returns
| A326030 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -3.8% | 1.5% | -1.6% |
| 1Y | 9.0% | 3.2% | -9.1% |
Return vs Industry: A326030 exceeded the KR Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: A326030 exceeded the KR Market which returned -9.1% over the past year.
Price Volatility
| A326030 volatility | |
|---|---|
| A326030 Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A326030 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A326030's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | n/a | Dong Hoon Lee | www.skbp.com |
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder.
SK Biopharmaceuticals Co., Ltd. Fundamentals Summary
| A326030 fundamental statistics | |
|---|---|
| Market cap | ₩8.11t |
| Earnings (TTM) | ₩57.38b |
| Revenue (TTM) | ₩511.33b |
139.1x
P/E Ratio15.6x
P/S RatioIs A326030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A326030 income statement (TTM) | |
|---|---|
| Revenue | ₩511.33b |
| Cost of Revenue | ₩51.20b |
| Gross Profit | ₩460.13b |
| Other Expenses | ₩402.75b |
| Earnings | ₩57.38b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 732.73 |
| Gross Margin | 89.99% |
| Net Profit Margin | 11.22% |
| Debt/Equity Ratio | 39.7% |
How did A326030 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 07:30 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SK Biopharmaceuticals Co., Ltd. is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dae Woong Yoo | Bookook Securities Co. Ltd |
| Seohyun Lee | Citigroup Inc |
| Sunghwan Kim | Credit Suisse |